Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome Measures

Abstract

Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.

Keywords::

• drusen
• geographic atrophy
• age-related macular degeneration
• clinical trials

ACKNOWLEDGMENTS

Declaration of interest: Dr. Rosenfeld receives ongoing research support from Alexion and has received research support from Potentia in the past. Dr. Albini has received research support from Neurotech in the past. Dr. Yehoshua has no financial or proprietary interest in the materials presented herein.